Acylhydrazide Derivatives for Orthopoxvirus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for orthopoxvirus infections, such as smallpox and monkeypox, face challenges including poor bioavailability, dose-limiting nephrotoxicity, and the emergence of resistant virus variants with existing antiviral compounds like cidofovir, as well as adverse effects and limited protection against recombinant strains with traditional vaccines.
Innovation Solution
Development of di, tri, and tetracyclic acylhydrazide derivatives and analogs that inhibit viral replication by targeting specific enzymes, offering improved bioavailability, reduced toxicity, and effectiveness against a range of orthopoxviruses, including resistant strains, with potential for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cidofovir is used to treat orthopoxvirus infections, then antiviral activity is achieved, but nephrotoxicity and poor bioavailability occur
Solution Approach 1:
The patent modifies the chemical structure of cidofovir by creating analogs with different substituents (R1-R6 groups) to alter pharmacokinetic properties and reduce nephrotoxicity while maintaining antiviral activity against orthopoxviruses
Solution Approach 2:
The invention develops composite chemical structures combining the core cidofovir moiety with various aromatic and heterocyclic groups to create molecules with improved therapeutic index and reduced renal toxicity
2Reliability
If traditional smallpox vaccines are administered, then protective immunity is achieved, but adverse effects occur and protection against recombinant strains is limited
Solution Approach 1:
The patent uses small molecule acylhydrazide compounds as intermediaries to provide antiviral protection without requiring live virus vaccination, thereby avoiding vaccine-related adverse effects while maintaining efficacy against both wild-type and recombinant orthopoxviruses
3Reliability
If existing antiviral compounds are used, then treatment effect is achieved, but resistant virus variants emerge
Solution Approach 1:
The patent systematically varies chemical parameters of the acylhydrazide compounds (substituents at different positions, ring structures) to create a series of analogs with different mechanisms of action, making it more difficult for viruses to develop resistance through single mutation events
Data Source
AI summary
Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.